$126,485,055

Department of Health and Human Services·Office of Assistant Secretary for Preparedness and Response

biotechactiveONGOING · MOD OF 2023 CONTRACT

WORK BEGAN2023-09-29·LATEST ACTION2026-03-23·SOURCEUSASPENDING·SOURCE IDCONT_AWD_75A50123C00045_7505_-NONE-_-NONE-

Award description

ADVANCED RESEARCH AND DEVELOPMENT ACTIVITIES FOR NOVEL IMMUNOGENICITY ASSAYS AND SAMPLE COLLECTION TECHNOLOGIES AS PART OF BARDA?S CONTINUING SUPPORT FOR COVID-19 VACCINE DEVELOPMENT, ASSESSING IMPACT OF VARIANTS ON VACCINE IMMUNOGENICITY, AND ANALYZ

Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.

The Buildout's read

What the model surfaced from this award

Confidence: high

In plain English

Latest obligation on a 2023 BARDA contract funding R&D into COVID-19 vaccine immunogenicity assays and sample collection technologies, including variant impact assessment.

Sub-sectors

mrna-vaccinescovid-19-responseimmunogenicity-assays

Why this matters

Sustains U.S. capacity to rapidly evaluate vaccine effectiveness against emerging variants and informs pandemic preparedness strategy.

Supply-chain signal

Supports domestic vaccine development infrastructure and diagnostic assay manufacturers; signals continued federal investment in rapid-response biotech capabilities.

U.S.–China competition angle

Reinforces U.S. leadership in mRNA vaccine science and variant surveillance—areas where China is accelerating domestic R&D.

Generated by award_classification v2.1.0 via claude-haiku-4-5-20251001 on 2026-05-25. Cost: $0.003064.

Period of performance

Start

2023-09-29

End

2029-09-28

Status

activein 1172 days

Recipient

PPD DEVELOPMENT LP

UEI ZANENSW6C665

View full profile →

Sources

USAspending.gov — all awards for this UEI →
SAM.gov entity registration →
Award record ingested from usaspending. Source identifier CONT_AWD_75A50123C00045_7505_-NONE-_-NONE-.

The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.